Abstract:Parkinson's disease is characterized by loss of dopamine neurons in the substantia nigra1. Similar to other major neurodegenerative disorders, there are no disease-modifying treatments for Parkinson's disease. While most treatment strategies aim to prevent neuronal loss or protect vulnerable neuronal circuits, a potential alternative is to replace lost neurons to reconstruct disrupted circuits2. Here we report an efficient one-step conversion of isolated mouse and human astrocytes to functional neurons by depleting the RNA-binding protein PTB (also known as PTBP1). Applying this approach to the mouse brain, we demonstrate progressive conversion of astrocytes to new neurons that innervate into and repopulate endogenous neural circuits. Astrocytes from different brain regions are converted to different neuronal subtypes. Using a chemically induced model of Parkinson's disease in mouse, we show conversion of midbrain astrocytes to dopaminergic neurons, which provide axons to reconstruct the nigrostriatal circuit. Notably, re-innervation of striatum is accompanied by restoration of dopamine levels and rescue of motor deficits. A similar reversal of disease phenotype is also accomplished by converting astrocytes to neurons using antisense oligonucleotides to transiently suppress PTB. These findings identify a potentially powerful and clinically feasible approach to treating neurodegeneration by replacing lost neurons.

Author Correction: Reversing a model of Parkinson’s disease with in situ converted nigral neurons

Reversing a model of Parkinson's disease with in situ converted nigral neurons (vol 53, pg 863, 2020)

Author Correction: Striatal neurons directly converted from Huntington's disease patient fibroblasts recapitulate age-associated disease phenotypes

Reversing a model of Parkinson's disease with in situ converted nigral neurons

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction: Corrigendum: Opportunities and challenges in modeling human brain disorders in transgenic primates

Author Correction: A growth-factor-activated lysosomal K+ channel regulates Parkinson’s pathology

Author Correction: Humanizing the Mdx Mouse Model of DMD: the Long and the Short of It

Correction To: Efficient and Rapid Conversion of Human Astrocytes and ALS Mouse Model Spinal Cord Astrocytes into Motor Neuron-Like Cells by Defined Small Molecules

Correction to: Inhibition of Dectin-1 Ameliorates Neuroinflammation by Regulating Microglia/Macrophage Phenotype After Intracerebral Hemorrhage in Mice

Erratum: A Stress-Induced Cellular Aging Model with Postnatal Neural Stem Cells

Corrigendum: Immediate modulatory effects of transcutaneous vagus nerve stimulation on patients with Parkinson's disease: a crossover self-controlled fMRI study

Corrigendum: Revisiting the L-dopa Response As a Predictor of Motor Outcomes after Deep Brain Stimulation in Parkinson's Disease

Correction: Reduced Topological Efficiency in Cortical-Basal Ganglia Motor Network of Parkinson's Disease: A Resting State Fmri Study.

Corrigendum: Uncovering the Pharmacology of Ginkgo Biloba Folium in the Cell-Type-specific Targets of Parkinson’s Disease with a Deep Learning Algorithm

Author Correction: C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Author Correction: Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy

Corrigendum: A progression analysis of motor features in Parkinson's disease based on the mapper algorithm

Correction to: The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis

Author Correction: Suppression of Glioblastoma by a Drug Cocktail Reprogramming Tumor Cells into Neuronal Like Cells

Author Correction: Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimer’s disease mouse model